(Total Views: 473)
Posted On: 09/08/2021 9:48:03 PM
Post# of 148878
Re: HHIGambler #103013
HHIG - it seemed very clear that CD17 might (will) start tomorrow, but that they don't consider it the important trial of the two. It has 600+ patients, I think, and they didn't emphasize the interim analysis. They implied that our benefit on severe patients could be modest, so they needed a lot of patients.
On CD16, they were very clear that they thought the interim analysis (around 116 or 160?) patients could be dynamite. That was exciting.
But, they were much less clear on the start date. "hopefully next week." But, really, they are waiting for Anvisa to review the IV stability information that was recently submittted. So, that could go fast, or it could go slow.
Is that a fair recap on these two trials?
On CD16, they were very clear that they thought the interim analysis (around 116 or 160?) patients could be dynamite. That was exciting.
But, they were much less clear on the start date. "hopefully next week." But, really, they are waiting for Anvisa to review the IV stability information that was recently submittted. So, that could go fast, or it could go slow.
Is that a fair recap on these two trials?
(0)
(1)Scroll down for more posts ▼
